Compare Energy Select Sector SPDR Fund (XLE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Energy Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Energy Select Sector SPDR Fund trades at $65.06 (market cap $40.84B), while Zoetis Inc trades at $74.58 (market cap $30.20B). The key difference: Energy Select Sector SPDR Fund is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Energy Select Sector SPDR Fund for 67 Days and Zoetis Inc for 70 Days on average.
| XLE | ZTS | |
|---|---|---|
Market Cap | $40.84B | $30.20B |
Volume | 50,409,268 | 6,175,327 |
52-Week High | $65.93 | $147.53 |
52-Week Low | $42.61 | $69.09 |
Typical Hold Time | 67 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLE trades at $65.27, up 2.98% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI at 70.16. The ETF, heavily concentrated in oil and gas, benefits from rising oil prices above $100 amid Middle East tensions and supply constraints. Recent news highlights strategic oil reserve releases and diesel price pressures, influencing energy sector volatility.
Outlook remains tied to oil price dynamics, with upside from sustained geopolitical risks but downside if crude reverses. Risks include oil market volatility and potential Fed rate hikes. Analyst sentiment is mixed, balancing energy sector strength against overbought technicals.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
